Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
By GlobeNewswire, July 10, 2017, 08:30:00 AM EDT
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilead's Vemlidy® (tenofovir alafenamide) in chronic Hepatitis B (HBV) patients.
"We are excited to be starting a new Phase 2 trial, which will be funded and implemented by Gilead Sciences and has the potential to accelerate the development program of SB 9200 as a potential backbone therapy for treatments focusing on functional cure in HBV," said Nezam Afdhal M.D., D.Sc., Chief Medical Officer of Spring Bank.
Although direct-acting antiviral drugs are effective in suppressing HBV replication, a functional cure in the treatment of chronic HBV has remained elusive. Spring Bank is developing SB 9200, a novel, selective oral immune-modulator which activates hepatic retinoic acid-inducible gene 1 (RIG-I), for the treatment of chronic HBV with the strategic concept that successful combination therapy for chronic HBV will require immune-modulation for a persistent and durable functional cure. In May 2017, Spring Bank released top-line results from the initial cohort of the Phase 2a segment of the ACHIEVE trial that suggested that a low dose (25mg) of SB 9200 alone may be able to reduce hepatitis B surface antigen (HBsAg) levels in patients with chronic HBV, a critical first step in achieving functional cure.
Dr. Afdhal continued, "We hope the combination of SB 9200 with Vemlidy will be synergistic in reducing HBsAg. This clinical trial partnership with Gilead is a continuation of our strategic efforts to engage in collaborations involving the study of SB 9200 in combination with other compounds against chronic HBV, and is an important next step in defining the most rapid path to potential Phase 3 development of new combination strategies for functional cure of HBV."
Under the terms of the clinical trial supply and collaboration agreement, Gilead will lead the Phase 2 trial with input from Spring Bank. Spring Bank will supply SB 9200 for the clinical trial.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the company's lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway. For more information, please visit www.springbankpharm.com.
2017年7月10日，马萨诸塞州霍普顿顿（GLOBE NEWSWIRE） - Spring Bank Pharmaceuticals，Inc.（纳斯达克股票代码：SBPH）是一家临床阶段的生物制药公司，目前正在开发用于治疗病毒感染，炎性疾病和某些癌症的新型治疗药物宣布与吉利德科学公司进行第二次临床试验合作，进行临床研究，研究使用Spring Bank的口服选择性免疫调节剂SB 9200，与Gilead的Vemlidy（替诺福韦甲酰胺）共同施用于慢性乙型肝炎（HBV）患者。
Spring Bank Pharmaceuticals是一家临床阶段的生物制药公司，致力于利用其专有的小分子核酸杂交（SMNH）化学平台发现和开发新一类治疗药物。 SMNH化合物是核酸的小部分，公司设计选择性靶向和调节涉及各种疾病状态的特定蛋白质的活性。该公司正在开发其最先进的SMNH产品候选人SB 9200，用于治疗病毒性疾病，包括乙型肝炎病毒（HBV）和其他SMNH产品候选人，包括SB 11285，该公司的首席免疫治疗药物，用于治疗选定的癌症激活INterferon基因的刺激因子或STING途径。欲了解更多信息，请访问www.springbankpharm.com。作者: kite2002005 时间: 2017-7-11 00:00